Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of chidamide (HBI-8000; Tucidinostat) in patients with hormone receptor-positive, HER-2 negative late stage breast cancer

Next Previous
X
Search
Trial Profile

A phase III trial of chidamide (HBI-8000; Tucidinostat) in patients with hormone receptor-positive, HER-2 negative late stage breast cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tucidinostat (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors GNT Biotech and Medicals Corporation

    • Most Recent Events

    • 21 Jun 2018 According to a GNT Biotech and Medicals Corporations media release, status changed from not yet recruiting to recruiting.
    • 20 Apr 2017 New trial record
    • 19 Apr 2017 According to a company media release, GNTbm will be using the same clinical trial protocol (see CT profile 258143) as used by Chipscreen Biosciences for this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top